Empliciti (elotuzumab) is an anti-cancer drug used to treat multiple myeloma in people who have tried other therapies. It is often combined with Pomalyst or Revlimid and a corticosteroid. Empliciti works by helping the immune system recognize and attack myeloma cells. It is administered as an intravenous infusion.

Common read more

Empliciti (elotuzumab) is an anti-cancer drug used to treat multiple myeloma in people who have tried other therapies. It is often combined with Pomalyst or Revlimid and a corticosteroid. Empliciti works by helping the immune system recognize and attack myeloma cells. It is administered as an intravenous infusion.

Common side effects include:
- Fatigue
- Diarrhea
- Fever
- Constipation
- Cough
- Cold or flu symptoms
- Nausea
- Loss of appetite
- Peripheral neuropathy
- Pneumonia

Rare but serious side effects include:
- Infusion reactions
- Increased risk for infection
- Increased risk for developing other cancers
- Liver damage

For more details, you can visit the Empliciti page on MyMyelomaTeam.

 This AI-generated response comes from MyMyelomaTeam and other selected sources. It is not a substitute for medical advice. Always ask your doctor about specific health concerns.

Empliciti (Elotuzumab) for Myeloma | MyMyelomaTeam

Darzalex (Daratumumab) for Myeloma | MyMyelomaTeam